Rocket Pharmaceuticals Inc (RCKT)

$3.64 -0.07 (-1.89%)
Market Cap 428.56M
Revenue (ttm) 0.00
Net Income (ttm) -258.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,217,000
Avg Vol 2,057,846
Day's Range N/A - N/A
Shares Out 108.22M
Stochastic %K 43%
Beta 0.47
Analysts Sell
Price Target $7.77

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
Autolus_Freakk
Autolus_Freakk Jan. 16 at 8:04 PM
$RCKT started accumulating, let's hope for $5 plus...
0 · Reply
mpap_
mpap_ Jan. 15 at 11:15 PM
$RCKT Good chances of approval for Kresladi. Solid Data. Real need for this ultra rare disease. If approved would also get a PRV, recently $JAZZ sold one for $200M . Extends runway without dilution. PT is $8-10 upon approval as may de=risk the company for the foreseeable future. If not approved then the stock will tank, runway just with cash only until 2027 Q2. As Martin Shkreli said once in his livestream, you don't want to have to beg for approval, you want to go in and have the FDA high five you and say "great job guys, making the USA proud". I think this fits this treatment and disease.
1 · Reply
oaksapollo
oaksapollo Jan. 15 at 6:16 PM
$RCKT towards the end Edelman says gene therapy is "underhyped" and we'll see some big wins there https://www.biotechtv.com/post/joseph-edelman-perceptive-advisors-january-15-2026
0 · Reply
TragicRain
TragicRain Jan. 15 at 4:40 PM
$RCKT - I like the March possibility - Opened up a position.
0 · Reply
BinaryLogic
BinaryLogic Jan. 15 at 6:31 AM
$RCKT
0 · Reply
CT_Biker
CT_Biker Jan. 14 at 7:34 PM
$RCKT Hmmm, I might start a position here.
2 · Reply
Biocontrol
Biocontrol Jan. 14 at 4:17 PM
$RCKT crazy pipeline here. Bought.
0 · Reply
FelixH86
FelixH86 Jan. 14 at 2:47 PM
$RCKT added
0 · Reply
johnkimble
johnkimble Jan. 14 at 12:46 PM
$RCKT can see well over $10 this year
0 · Reply
Bennyman369
Bennyman369 Jan. 14 at 1:16 AM
$RCKT
0 · Reply
Latest News on RCKT
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 5:16 PM EST - 2 days ago

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 11 days ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

Dec 26, 2025, 10:23 AM EST - 21 days ago

Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 7 weeks ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 4:00 PM EST - 2 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Oct 14, 2025, 2:27 PM EDT - 3 months ago

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:00 PM EDT - 3 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Oct 3, 2025, 7:11 AM EDT - 3 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:36 PM EDT - 4 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 5 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 11:02 AM EDT - 5 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Aug 20, 2025, 9:31 AM EDT - 5 months ago

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:09 AM EDT - 5 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 20, 2025, 7:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 8, 2025, 2:16 PM EDT - 5 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 5 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 30, 2025, 6:29 PM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 6 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA QURE

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 29, 2025, 10:26 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 25, 2025, 3:02 PM EDT - 6 months ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Jul 24, 2025, 4:02 PM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 24, 2025, 7:00 AM EDT - 6 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 17, 2025, 7:00 AM EDT - 6 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 11, 2025, 10:25 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 6 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jul 7, 2025, 9:00 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Autolus_Freakk
Autolus_Freakk Jan. 16 at 8:04 PM
$RCKT started accumulating, let's hope for $5 plus...
0 · Reply
mpap_
mpap_ Jan. 15 at 11:15 PM
$RCKT Good chances of approval for Kresladi. Solid Data. Real need for this ultra rare disease. If approved would also get a PRV, recently $JAZZ sold one for $200M . Extends runway without dilution. PT is $8-10 upon approval as may de=risk the company for the foreseeable future. If not approved then the stock will tank, runway just with cash only until 2027 Q2. As Martin Shkreli said once in his livestream, you don't want to have to beg for approval, you want to go in and have the FDA high five you and say "great job guys, making the USA proud". I think this fits this treatment and disease.
1 · Reply
oaksapollo
oaksapollo Jan. 15 at 6:16 PM
$RCKT towards the end Edelman says gene therapy is "underhyped" and we'll see some big wins there https://www.biotechtv.com/post/joseph-edelman-perceptive-advisors-january-15-2026
0 · Reply
TragicRain
TragicRain Jan. 15 at 4:40 PM
$RCKT - I like the March possibility - Opened up a position.
0 · Reply
BinaryLogic
BinaryLogic Jan. 15 at 6:31 AM
$RCKT
0 · Reply
CT_Biker
CT_Biker Jan. 14 at 7:34 PM
$RCKT Hmmm, I might start a position here.
2 · Reply
Biocontrol
Biocontrol Jan. 14 at 4:17 PM
$RCKT crazy pipeline here. Bought.
0 · Reply
FelixH86
FelixH86 Jan. 14 at 2:47 PM
$RCKT added
0 · Reply
johnkimble
johnkimble Jan. 14 at 12:46 PM
$RCKT can see well over $10 this year
0 · Reply
Bennyman369
Bennyman369 Jan. 14 at 1:16 AM
$RCKT
0 · Reply
Doccjc62
Doccjc62 Jan. 13 at 6:44 PM
$RCKT Decent day so far
1 · Reply
Quantumup
Quantumup Jan. 13 at 12:20 PM
Oppenheimer reiterated $LXEO Outperform-$20 $RCKT $TNYA $LRMR $BIIB VYGR DSGN PTCT Oppenheimer said in its note: We believe yesterday's interim look from LX2020's Phase 1/2 HEROIC study in PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) yielded clear efficacy signals across the high-dose cohorts accompanied by unconcerning safety observations. With shares having closed down 23% vs. a flat XBI, the market may have been looking for a more consistent relationship between PKP2 increase and arrhythmia improvement-but we emphasize that the data remain immature, and look forward to 12-month follow-up results from all high-dose participants in 4Q26. We regard the selloff as having made the shares more attractive in view of LX2006's opportunity in Friedreich's ataxia ($1B+ US peak sales opportunity), which remains the key LXEO investor focus in our view and for which Phase 2 remains on track to begin in 1H.
1 · Reply
darntootin
darntootin Jan. 13 at 12:52 AM
$RCKT While both studies are modern, single-arm trials for ultra-rare diseases, there are key clinical and regulatory differences that support the view that Rocket’s Krezladi study (RP-L201) has a more definitive data set than Atara’s Tab-cel study (ALLELE). 1. Strength of Primary Outcomes Rocket (Krezladi): Achieved a 100% overall survival rate at 12 months for all nine treated patients. In severe LAD-I, historical untreated survival is roughly 25-40% by age two, making 100% survival a clear and dramatic clinical success. Atara (Tab-cel): Demonstrated a 48.8% to 51.2% Objective Response Rate (ORR). While significant, an "objective response" (tumor shrinkage) is more difficult to interpret in a single-arm study than a "survival" endpoint, especially when the FDA recently questioned how much of that response was directly caused by the drug.
1 · Reply
Plowmaster
Plowmaster Jan. 12 at 10:43 PM
$RCKT seeing pressure along with the rest of biotech today. No company-specific news that changes the setup. Feels tied to JPM conference volatility and the broader selloff after the FDA ATRA reversal. Thin float and heavy positioning make moves like this get amplified. This is also why I never put anything above an 80% approval probability. The FDA is made up of people, and people are variable no matter what’s been said before. You can spin theories on why decisions change, but at the end of the day you just move forward. Longer-term thesis here looks the same to me. Buy the dips
0 · Reply
BulICrunch
BulICrunch Jan. 12 at 7:52 PM
$RCKT PDUFA in march, update on danon in the first half, expect a run at these levels
0 · Reply
BulICrunch
BulICrunch Jan. 12 at 7:47 PM
$RCKT @CharlieeMungerTWITS play this one baby
1 · Reply
oaksapollo
oaksapollo Jan. 12 at 3:54 PM
$RCKT I think the more relevant piece of news is that FDA is relaxing CMC standards for cell and gene therapies. CMC is why Rocket got the CRL. I would argue the Atara cell therapy news is not relevant (Rocket does not do cell therapy) and the relaxation of CMC rules all but assures approval in March. That being said, the fact that FDA can no longer be trusted is VERY CONCERNING for ALL OF PHARMA.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 12 at 3:49 PM
$RCKT maybe a bit weak on this
0 · Reply
IberianBullish
IberianBullish Jan. 12 at 12:23 PM
$AUTL $EDIT $RCKT $RGNX $SGMO Lol, interesting how the one you’re short is the only one that “doesn’t benefit.” This FDA news is clearly bullish for SGMO — looks more like bearish bias than analysis.
1 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Jan. 12 at 11:20 AM
$SGMO FDA announcement is bullish to the 100’s of cell and gene therapy companies on the market: $RGNX, $RCKT, $EDIT, $AUTL etc etc etc SGMO is NOT one of them, they are bearish, no money, bankrupt
1 · Reply
MaxPower1987
MaxPower1987 Jan. 12 at 5:50 AM
$RCKT
0 · Reply
pjapak
pjapak Jan. 11 at 8:17 PM
$RCKT This news is especially for Rocket. https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation?utm_medium=email&utm_source=govdelivery
1 · Reply